Acer Therapeutics (NASDAQ:ACER) – William Blair upped their Q2 2018 earnings per share (EPS) estimates for shares of Acer Therapeutics in a research report issued on Tuesday, May 15th. William Blair analyst T. Lugo now anticipates that the biopharmaceutical company will post earnings per share of ($0.57) for the quarter, up from their previous forecast of ($0.83). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Acer Therapeutics’ Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.57) EPS, FY2018 earnings at ($2.22) EPS, FY2019 earnings at ($1.13) EPS and FY2020 earnings at $1.23 EPS.
Acer Therapeutics (NASDAQ:ACER) last issued its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.16.
Shares of ACER opened at $19.82 on Thursday. Acer Therapeutics has a one year low of $18.40 and a one year high of $18.40. The company has a market cap of $136.90 million, a P/E ratio of -5.16 and a beta of 2.36.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACER. Perceptive Advisors LLC acquired a new position in Acer Therapeutics during the fourth quarter worth $2,091,000. J. Goldman & Co LP acquired a new position in Acer Therapeutics during the fourth quarter worth $1,496,000. Stonepine Capital Management LLC acquired a new position in Acer Therapeutics during the fourth quarter worth $1,385,000. Heartland Advisors Inc. acquired a new position in Acer Therapeutics during the first quarter worth $1,071,000. Finally, Neuberger Berman Group LLC acquired a new position in Acer Therapeutics during the first quarter worth $385,000. 7.68% of the stock is currently owned by institutional investors.
About Acer Therapeutics
Acer Therapeutics Inc develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.